The Accelerating Medicines Partnership (AMP), is a pre-competitive collaboration among government, academia, and industry to improve the ongoing efforts to develop new therapies for complex, heterogeneous diseases (http://www.nih.gov/science/amp/). The overarching goal of AMP CMD is to use human genetics as a powerful approach to obtain human-data derived disease understanding and biomarker/therapeutic opportunities. This is being accomplished through systematic aggregation of existing genotype-phenotype data for CMD, related traits, and its complications as well as the generation of a large amount of new omic data. The goal of the NIDDK-funded component of the consortium is to aid in advancing the understanding of the mechanisms responsible for T2D development through the integration of large-scale genetic data that will contribute to further deconstruction of the pathophysiology of T2D, and potentially of its major complications, including macrovascular and microvascular disease. The purpose of this is to request is for renewal of the AMP CMD UM1 program for another 5 years for the portal to aggregate and collate data on T2D/CMD genes and their functional variants so that it can be queried by the scientific community.

Education

• Public and state institutions of higher education
• Independent school districts
• Private institutions of higher education

Government

• Federally recognized Native American tribal governments
• Special district governments
• State governments
• County governments
• Public and Indian housing authorities

Business

• For-profit organizations other than small businesses
• Small businesses

Nonprofit

• Nonprofits non-higher education with 501(c)(3)
• Other Native American tribal organizations